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Available online 10 May 2016Microphysiological systems (organs-on-chips, tissue chips) are devices designed to recapitulate human physiol-
ogy that could be used to better understand drug responses not easily addressed using other in vivo systems or
in vitro animalmodels. Although still in development, initial results seempromising as tissue chips exhibit in vivo
systems-like functional responses. The National Center for Advancing Translation Science (NCATS) identiﬁes this
technology as a potential tool that could improve the process of getting safer, more effective treatments to pa-
tients, and has led to the Tissue Chip Program,which aims to develop, integrate and validatemajor organ systems
for testing. In addition to organ chip development, NCATS emphasizes disseminating the technology to re-
searchers. Commercialization has become an important issue, reﬂecting the difﬁculty of translation from discov-
ery to adoption and wide availability. Therefore, NCATS issued a Request for Information (RFI) targeted to
existing partnerships for commercializing tissue chips. The goal was to identify successes, failures and the best
practices that could provide useful guidance for future partnerships aiming tomake tissue chip technologywide-
ly available.
© 2016 Livingston et al.. Published by Elsevier B.V. on behalf of the Research Network of Computational and







RFI: Request for informationPrimary obstacles to the development of new therapeutic drugs are
the signiﬁcant time and resources required to identify and reﬁne new
compounds, the lack of better in vitro and in vivo models that are able
to accurately predict the safety and efﬁcacy of candidate therapeutics
in humans, and submission of the data needed for Food and Drug
Administration (FDA) regulatory approval [1–3]. The needed capital in-
vestment, coupled with high failure rates in clinical trials, makes phar-
maceutical development high risk [3–5]. Many compounds ultimately
fail in clinical trials due to toxicity or lack of efﬁcacy in humans that is
not evident in preclinical data from in vitro or animal testing [6]. To in-
crease the rate at which promising compounds are identiﬁed and to re-
duce the number of compounds that fail in costly and time-consuming
clinical trials, the National Center for Advancing Translational Sciences
(NCATS) at the National Institutes of Health (NIH) in collaboration
with the Defense Advanced Research Projects Agency (DARPA) and
the FDA, initiated theNIH Tissue Chip for Drug Screening Program tode-
velop human microphysiological organ systems (MPS) for toxicity and
efﬁcacy testing.B.V. on behalf of the Research Netwo
0/).The Tissue Chip (TC) Program is to develop human tissue or organ
systems (e.g., heart, liver, kidney, nervous system) on bioengineered
platforms (i.e., “chips”) [7]. The platforms support the key functional el-
ements (such as 3D tissue architecture, multi-cellularity, biomechanical
transduction properties, etc.) of organs under conditions that mimic the
physiological and mechanical environment found in vivo, and are de-
signed to facilitate functional readouts (e.g., cardiac contractility, gene
expression) [4,8–14]. A long term objective is to integrate multiple
organ system platforms into a “human on a chip” for a more com-
prehensive evaluation of drug toxicity and efﬁcacy (Tissue Chip-
Integration) [14–17]. The development and integration of “organs on
chips” requires multidisciplinary collaboration of basic scientists, clini-
cians and bioengineers [10,11,13,14,18]. These collaborations have
been facilitated greatly by productive public–private partnerships that
advance the interests of both sectors. To foster additional partnerships
and to identify factors contributing to their success, NCATS issued a
Request for Information (NOT-TR-14-008, Public–Private Partnerships
for Organ Systems and Platforms Developed by Microphysiological Systems
(MPS) Investigators). In this report we summarize the responses, which
reveal not only factors contributing to success, but also highlight broad
interest in the further development, adoption and availability of the tis-
sue chip technology for pharmaceutical development and research
purposes.rk of Computational and Structural Biotechnology. This is an open access article under the
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Many partnershipswithin the TC Program include academic and pri-
vate sector scientists with mutual interests in the development of the
organ systems and in advancing the design of the bioengineered plat-
forms. In some cases, NIH and DARPA-funded academic scientists have
contributed biological expertise and provided feed-back related to de-
sign requirements, while private sector participants contributed engi-
neering expertise, production efﬁciency and marketing experience.
The collaborative aims of the public and private sectors are further re-
ﬁnement and marketing of the microphysiological organ systems and
platforms as relevant research and testing tools. Participants in produc-
tive partnerships that achieve these aims consistently cite certain fac-
tors that contribute to their success: 1) opportunities for balanced
contributions andmutual beneﬁts for both the private and public partic-
ipants; 2) an organized leadership team with well-deﬁned roles; 3) ef-
fective communication between basic scientists, engineers and senior
members of the leadership team; 4) productive exchangewith potential
stakeholders; 5) early identiﬁcation of a targetmarket; and 6) early con-
sideration of collaborative agreements that address intellectual proper-
ty issues.
The most productive TC public-private partnerships are based on
balanced contributions and subsequent beneﬁts for all. Most important-
ly, public and private partnersﬁrst need to identify and align their goals.
Additional approaches to balanced contributions are discussed below.
The beneﬁts for public and private partners aremore rapid scientiﬁc de-
velopment and adoption of the organ systemplatforms, with the poten-
tial for scientiﬁc advances and ﬁnancial proﬁt. The most successful
partnershipsmay lead towidespread use of tissue chips by the pharma-
ceutical industry, adoption for toxicology testing, and translation for
clinical applications (e.g., personalized or precision medicine).
Optimally, partnerships are built on an organized leadership team
with each member having a well-deﬁned role. Experienced individuals
serving in leadership roles can articulate objectives clearly and focus
team efforts. Themost efﬁcient partnerships include a small group of se-
lect individuals serving as team leaderswho can identify primary objec-
tives, integrate them, and direct development. Proximity of leadership
and private sector partners to basic and clinical scientists is advanta-
geous in the early stages of development, as this facilitates discussion,
testing, access to clinical resources, and can eliminate “middlemen.”On-
going feedback from private sector partners based on their knowledge
of manufacturing and marketing is critical for later stages of develop-
ment. The integration of this feedback and that from publically funded
biomedical scientists is essential to achieving long-term objectives.
Effective communication between publically supported TC scientists
and private sector partners is necessary to assure both scientiﬁc validity
and that organ system platformswill meet market needs. Early identiﬁ-
cation of the key features required and goals for use of the platforms is
essential for efﬁciency and aggregate solutions, leading to well integrat-
ed design. The functional read-outs that are needed should be identiﬁed
ahead of time, ideally with input from public, private and regulatory
sectors. Platform design is driven in part by requirements for validation,
but also by the organ systems' and/or platforms' intended use(s). They
may be designed for a narrowly targetedmarket, or allow for modiﬁca-
tions tomeet the needs of a broadermarket. For example large pharma-
ceutical companies may have a wide variety of applications for ex vivo
organ systems, dictating that a range of platform options be available:
they may need 2- or 3-dimensional systems, single or paired organ sys-
tem platforms, or multi-organ integrated platforms. Design priorities
that consider the scientiﬁc validity of the organ systemswhile balancing
market demand should be determined early in development.
In addition to communication between scientists and engineers
partnering to develop and/or market the tissue chips, valuable input
may come also from stakeholders and early consumers. Therefore, dur-
ing early translation of the organ systems and platforms to consumers, it
is advantageous to anticipate an extended period of technical supportand discussion. This facilitates closer collaboration between engineers
and biologists, and between developers and consumers, leading to
more rapid improvements in design and assurance that the devices
meet requirements. Importantly, private sector partners should be pre-
pared to provide a high level of technical support, particularly in the
early marketing phase.
As a target market is identiﬁed, demonstrating the proﬁt potential
may be necessary to attract investors. These markets may include the
pharmaceutical/biotechnology, research or clinical sectors. Thepharma-
ceutical or biotechnology sectors, acting as service providers, are likely
to use the organ systems and/or platforms for preclinical assays. This
may be the most proﬁtable market initially and therefore likely to at-
tract the largest capital investment. Alternatively, the research sector
may implement the organ systems and/or platforms as tools. This sector
may represent numerous users, but is likely to provide a lower proﬁt
margin andmay bemore attractive to smaller investors. The clinical sec-
tor, using the organ system platforms for diagnostics and individualized
medicine applications, may be limited initially, but has much potential
for growth. Until an organ system platform is validated and progresses
towards regulatory qualiﬁcation, this market may attract limited ﬁnan-
cial support. Larger investments in products targeting the clinical sector
may not occur until development by smaller biotechnology ﬁrms has
progressed far enough to establish a viable clinical market. Notably,
the features of the organ system platforms required by each of these
sectors will be different and may dictate shifts in design and develop-
ment as each market comes to the forefront. Parallel development of
platforms for different uses and multiple markets should be feasible.
In parallel with the scientiﬁc development and engineering of the
organ system platforms, it is imperative that both academic and private
sector partners give early consideration to legal issues and to a business
plan. These should be addressed early to avoid later complications that
would delay scientiﬁc progress or the broader distribution of this novel
technology. For example, provisions for conﬁdentiality and intellectual
property must be agreed upon in the early stages of development, in
consultation with institutional and corporate legal representatives.
Agreements should address issues such as patenting, licensing arrange-
ments, revenue sharing, and when appropriate, NIH resource sharing
requirements. Once a good legal plan is established, it can serve as a
general model for future partnership agreements.
2. Regulatory considerations
A key incentive for private sector participation and investor interest
is regulatory qualiﬁcation and validation of the organ system platforms.
Validation processes will depend on the intended use of the TCs, either
as a stand-alone approach (e.g., precision medicine) or as one element
in an integrated set of approaches (e.g., dose–response, toxicity and ef-
ﬁcacy testing) [4,14–16]. The TCs may be used as a tool for mechanistic
studieswith a reduced number of variables [12]; theymaybe developed
for preliminary or efﬁcient dose–response testing for efﬁcacy and off-
target effects, thus reducing the cost of drug development [19]; or TCs
developed from human cells can serve as a preclinical approach to iden-
tify compounds whose efﬁcacy or toxicity is different in animal vs.
human tissue [4,8,9,20]. As an example of the latter, TCs can illustrate
signiﬁcant differences in hepatotoxicity in animals vs. humans [21,22].
Validation of human organ chips for any use will be a complex pro-
cess, requiring a long term commitment to the goal of the FDA qualify-
ing theMPS as a valid research tool. Ultimately, validation will require a
comparison of the toxicity and efﬁcacy data for compounds tested in
preclinical animal studies, using the human tissue chip platforms, and
in clinical trials. Demonstration that the results of testing using human
microphysiological organ systems parallel those from clinical trials is
critical for regulatory approval. Demonstration that the TC platforms
can be used to identify toxic or ineffective compounds that have failed
in human clinical trials despite promising preclinical data from animals
would incentivize the market and investors.
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consideration of tissue chip technology. As the organ systems and relat-
ed tools are reﬁned, input and guidance from the FDAwill be needed; in
parallel, participation by the pharmaceutical industry will also help to
determine speciﬁcations and to identify biomarkers for which FDA ap-
provals are needed. Several approaches are likely to stimulate input
from the FDA. First, promoting more widespread use of the TC plat-
forms, so that data from thembegin to appearmore regularly in FDA ap-
plicationswill lead to greater familiarity and understanding of the tissue
chip technology. The submission of reliable data from TCs will generate
more conﬁdence in this new technology. This may not be adequate as
“stand alone” evidence: initially, data from MPS may be most effective
when submitted as complementary to other models. High quality data
from MPS that are consistent with that derived from other approaches
will provide initial evidence for the reliability of this new technology,
and will allow agencies to evaluate the utility and current limitations
of this approach. Importantly, the submission of data derived from
MPS to regulatory agencies can support the use of this technology to an-
swer questions that cannot be addressed using animal models. For ex-
ample, TCs may be particularly useful for determining the mechanism
of drug action and relevance in human systems.
This leads to a second approach for soliciting input from regulatory
agencies such as the FDA. As part of its Critical Path program, the FDA
developed the Biomarker Qualiﬁcation Program (Drug Development
Tools – Biomarker Qualiﬁcation Program); validation of individual bio-
markers on individual chips may be a key step towards qualiﬁcation
and acceptance of tissue chips. Qualiﬁcationmay result in FDA clearance
to market the tissue chip technology as a tool for therapeutics develop-
ment; this could occur long before FDA acceptance of the technology as
a clinical diagnostic or treatment tool (e.g., individualized medicine).
Importantly, consortia such as the TC Program could be an important el-
ement in biomarker qualiﬁcation applications. Thirdly, immediate use
of the tissue chip technology may be pursued via the FDA's Investiga-
tional New Drug (FDA Investigational New Drug [IND] Application) or
New Drug Application (New Drug Application [NDA]) procedures; ap-
proval via these pathways will require investigators' documentation
and validation of key biomarkers that focus on well-known pathologies
(e.g., arrhythmia, contractility, troponin release). Lastly, the NIH and TC
Consortium could consider working with the FDA via its Broad Agency
Announcement (BAA)/Program for Extramural Regulatory Science and
Innovation (PERSI; FDA Program for Regulatory Science and Innova-
tion). Several of the TC Program objectives coincide with the regulatory
research areas targeted for advanced development by the FDA's PERSI:
improved toxicological approaches to increase therapeutic safety; inno-
vative approaches to clinical evaluation to improve product develop-
ment and personalized medicine for improved patient outcomes; and
improved approaches to the evaluation of therapeutics' quality.
3. Roles of the NIH and Tissue Chip Consortium
In response to the question of what the NIH and NCATS can do to fa-
cilitate TC Investigators' progress and the development of strategic
public–private partnerships, respondents cited two roles. First, NCATS
might coordinate the identiﬁcation of tools, resources and protocols
that are common requirements for TC Investigators. The TC consortium
has the potential to leverage members' collective data for consensus-
based solutions and device-development, and might play an important
role in identifying reliable sources for common requirements and in fa-
cilitating access to them.
Among the requirements for the TC Program is a reliable source of
cells, in particular human induced pluripotent stem cells (hiPSC), to
serve as a renewable tissue source from which the organs on chips
can be developed. Compiling input from TC investigators, NCATS
might assist in setting standards for the characterization of and reliable
access to hiPSC for investigators whowish to adopt the tissue chip tech-
nology. Standardized differentiation protocols also may be useful.Collectively reliable access, careful hiPSC characterization and opti-
mized differentiation protocols will ensure reproducibility, thus con-
tributing towards standardization of the tissue chips and making them
amore attractive technology for research and testing laboratories. A col-
laborative approach towards these requirements has proven extremely
valuable in developing single organ systems. The additional complexi-
ties of multi-organ integration (i.e., multiple tissue types and differenti-
ation protocols) would present a signiﬁcant hurdle to adoption of the
organ platform technology by any single entity, in particular those
with limited resources for research and development. A consortium of
investigators with broad expertise could address these complex prob-
lems more efﬁciently.
A contract awarded to a private sector company or contract research
organization may be one way to ensure availability of a repository of
cells appropriate for the tissue chips. Important considerations would
be the contract recipient's responsibility for: 1)maintaining a repository
of well-characterized, cryopreserved cells, 2) their proliferation, 3) dif-
ferentiation, and 4) distribution. The repository should include cell
lines andhiPSC that have been usedwidely by the pharmaceutical or re-
search sectors; these cells are characterized already and prior data sets
are available for functional evaluation. Multiple organizations and pri-
vate companies have acquired thousands of cells derived from control
and diseased donors; many of these could bemade available for TCs, ei-
ther for research or testing purposes, through transfer agreements
established through the repository. Further, contracts associated with
cell repositories may require technical support and the incorporation
of biomarkers and reporters into cells. Relatedly, it is important that
the potential impact of reporters or biomarkers on cell function be eval-
uated and documented; again, input from regulatory agencies regarding
approval of biomarkers in cell lineswill be critical. If the tissue chip tech-
nology is to be developed for personalized medicine, standardized pro-
tocols for cell differentiation should be established, and procedures for
distribution and technical support established. Contracts must be ﬂexi-
ble andmodiﬁable to allow inclusion of additional cell types as they are
needed. Commercial repositories could bemanagedwith ongoing input
from academic scientists, the biotechnology sector, and the pharmaceu-
tical industry to deﬁne current requirements.
With the establishment of resources such as cell repositories and
databases for the TC Consortium, ethical and legal issuesmust be consid-
ered. As cell repositories are established, investigators and contractors
must consider issues such as informed consent, donor permission, IRB
approval, and permission/licensing issues related to use of de-identiﬁed
cells. As databases are established, the need to facilitate information ex-
changemust be balancedwith the need for security (i.e., donor conﬁden-
tiality, access privileges) and protection of intellectual property. For
example, the presentation of information via website, even if access is
limited, can adversely impact subsequent patent protection.
A strength of NCATS is the ability to mediate partnerships by facilitat-
ing introductionswith the private sector and to foster such collaborations,
which could beneﬁt the TC Consortium.When appropriate, open sessions
may be incorporated as a component of TC Investigator meetings; these
sessionsmight be announced to attract partners, stakeholders and poten-
tial investors. Also, workshops focused on the status of MPS, regulatory
agency insight and industry perspectives are encouraged. International
interactions with NCATS related to tissue chip development may be par-
ticularly important given pressing European Union requirements related
to animal testing and research efforts to develop alternative approaches
[23]. The NIHmight also organize symposia or other presentations at na-
tional scientiﬁc meetings on MPS that are relevant to different scientiﬁc
disciplines. Such symposia are likely to attract the attention of re-
searchers, clinicians and industry, and facilitate strategic collaborations.
4. Scenario for commercialization
In summary, responses solicited by the NCATS' Request for Informa-
tion identify several approaches to TC public–private partnerships:
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velop an individual organ on a chip, 2) partnerships for the develop-
ment of speciﬁc resources needed by the Tissue Chip Consortium
(e.g., cell lines, microﬂuidic components, perfusion media), and 3) pri-
vate sector maintenance of renewable resources such as cell reposito-
ries, data bases, or standardized protocols. In addition to coordinating
the efforts of TC Consortium members, it is suggested that the NIH can
facilitate public–private partnerships via subcontracts on individual
grant awards or cooperative agreements. The NIH can also attract
small business concerns through its Small Business Innovation Research
(SBIR) and Small Business Technology Transfer (STTR) grants and
contracts.
To attract private partners, an investigator will need a minimal, but
viable technology for which there is some proof of concept, and a dem-
onstrated commitment to development. A system or technology that is
not yet validated or FDA-approved is not necessarily a roadblock to
partnership; many smaller private sector entities are willing to contrib-
ute towards development to move the technology forward for SBIR/
STTR funding, and eventual submission to the FDA. Initial funding of a
partnership may be through government support (i.e., subcontract,
SBIR/ STTR programs) or angel investors. At this stage it is important
to identify a usermarket and to develop amarketing strategy; as devel-
opment proceeds, the strategy may be modiﬁed in response to de-
mands. With input from regulatory agencies, work should proceed
towards product validation, adoption for use, FDA biomarker qualiﬁca-
tion or IND/NDA approval. This may be an iterative process involving
further research and development, duringwhich a publically funded in-
vestigator who is developing an organ system platform will beneﬁt by
the data generated and published, while a private sector partner will
beneﬁt by increased product visibility. Focus should then be on further
reﬁnement of the business plan, identifying and attracting investors ap-
propriate for the potential revenue ﬂow. If successful, the market share
might be increased by modiﬁcations or further reﬁnement of the plat-
forms to expand their utility, diversiﬁcation of the product line, or ex-
tending the network of contacts (e.g., international cooperation might
be a consideration).
5. Partnerships associated with the Tissue Chip program
Clearly, both public and private partners can beneﬁt from the more
rapid development of organ system platforms and achieving their
collaborative aims. Communication with regulatory agencies will pro-
vide additional beneﬁt by helping to identify speciﬁc goals for further
reﬁnement and validation of tissue chip technology. Input from all
stakeholders will be needed tomove the TC Program beyond the devel-
opment of individual and integrated MPS towards deﬁned context of
use, standardization and validation. Therefore future partnerships will
require the inclusion of broad and complementary expertise from vari-
ous scientiﬁc and professional disciplines to assure access to and easy
adoptability of the tissue chips for translational scientiﬁc (e.g., disease
modeling) and clinical use (e.g., personalized or precision medicine).
NCATS has begun to lay the groundwork for such partnerships to fa-
cilitate adoption of the organ system platforms as relevant models inbiomedical research. Material Transfer Agreements (MTAs) with phar-
maceutical companies are to provide TC Consortium Investigators
with access to proprietary compounds, including those that failed in de-
velopment due to toxicity in vivo. The next step will be to determine if
the organ systems can replicate responses previously observed in vivo.
Furthermore, Memorandums of Understanding (MOU) were executed,
allowing pharmaceutical and small industry representatives to interact
with Tissue Chip researchers regarding the use andmarketing of current
MPS technology. These interactions are crucial to facilitate feedback
from potential stakeholders and to identify technical requirements
early. Insights resulting from these interactions will help to redeﬁne
microphysiological systems as valid research tools and to make then
widely available to the scientiﬁc community.Acknowledgements
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